Asia
The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people.
The latest funding round gives XtalPi $20M in the bank, which the company said makes it “one of the top-funded AI-powered biotechs.”
China researchers have treated 86 cancer patients with genetically modified versions of their own immune cells.
Sinocare of Changsha may bid as much as $4B to acquire J&J’s diabetes medical device subsidiaries
The company will use the money to fund clinical trials and develop a marketing operation.
Celltrion, the little-known South Korean biotech company that surged into the ranks of the world’s most-traded stocks at the start of 2018, may finally be coming down to Earth.
The cuts are being made as the company grapples with a debt of between $30 and $35B and a restructuring of its R&D in order to combat dramatically declining revenue from its generic pipeline.
Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly.
An online comment can spur some serious discussion.
Innovent Biologics of Suzhou is planning a pre-IPO round and then an IPO for $200M in late 2018.
PRESS RELEASES